Department of maxillo-facial surgery and stomatology, Pitié-Salpétrière hospital, Pierre-et-Marie-Curie university Paris 6, Sorbonne Paris Cite university, AP-HP, 75013 Paris, France; Department of otolaryngology and head and neck surgery, Changeux Building, Simone-Veil hospital, 14, rue de Saint-Prix, 95600 Eaubonne, France.
Department of otolaryngology and head and neck surgery, Changeux Building, Simone-Veil hospital, 14, rue de Saint-Prix, 95600 Eaubonne, France.
J Stomatol Oral Maxillofac Surg. 2020 Nov;121(5):550-555. doi: 10.1016/j.jormas.2020.03.008. Epub 2020 Mar 20.
Surgical revision rate of rhinoplasty is from 5% to 15% in literature.
In the context of post-rhinoplasty deformities, we aim to investigate the modalities of using injectables, their impacts on revision rate of rhinoplasty as well as their influences on the surgical strategy.
We realized an international literature review to collect informations on main studies reporting series of exclusive secondary medical rhinoplasties or mixed primary/secondary medical rhinoplasties, as well as per-operative injection.
The databases of the National Library of Medicine, Cochrane Library, Embase and Web of science were explored using the following Boolean string: (rhinoplasty OR nose) AND (injectable OR fillers OR hyaluronic acid OR calcium hydroxylapatite). The search was limited to the English language literature for studies published from 2007 up to December 2019.
Fifteen cohort studies were included. Hyaluronic acid was the most commonly used injectable for rhinoplasty revision. Patient satisfaction rates varied between 80% and 100%. Reinjections were necessary in about 20 to 50% of cases whatever the used injectables. Minor complications (swelling, bruising, erythema) were frequent after filler injections (4%). Severe complications such granulomas or vascular embolism causing skin necrosis/visual impairment were rare (0.4%). Their physiopathology, management and prevention are detailed.
The use of injectables seems to reduce the need of secondary surgical rhinoplasties. It can be expected that an evolution in surgical practices will result from injectables using, but it will be possible only if the technique is perfectly understood to avoid potentially serious vascular complications.
文献报道的鼻整形术修复率为 5%至 15%。
在鼻整形术后畸形的情况下,我们旨在研究使用注射剂的方式、它们对鼻整形术修复率的影响以及对手术策略的影响。
我们进行了一项国际文献综述,以收集主要研究的信息,这些研究报告了专门的二次医疗性鼻整形术或混合的原发性/二次医疗性鼻整形术系列,以及术中注射。
使用以下布尔字符串在国家医学图书馆、考科兰图书馆、Embase 和 Web of science 数据库中进行搜索:(鼻整形术或鼻子)和(注射剂或填充物或透明质酸或羟基磷灰石)。搜索仅限于 2007 年至 2019 年 12 月发表的英语文献。
共纳入 15 项队列研究。透明质酸是鼻整形术修复最常用的注射剂。患者满意度在 80%至 100%之间不等。无论使用何种注射剂,约有 20%至 50%的病例需要再次注射。填充物注射后常出现轻微并发症(肿胀、瘀伤、红斑)(4%)。严重并发症如肉芽肿或血管栓塞导致皮肤坏死/视力障碍罕见(0.4%)。详细介绍了它们的发病机制、处理和预防。
使用注射剂似乎可以减少二次手术鼻整形术的需求。可以预期,随着注射剂的使用,手术实践将会发生演变,但只有当技术被完美理解以避免潜在的严重血管并发症时,这种演变才有可能发生。